Carboplatin (CBDCA), 5-fluorouracil (5-FU) and mitoxantrone (DHAD): An effective and well tolerated regimen for metastatic breast cancer
| Autor: | O. F. Hidalgo, F. G. Gonzalez, E. Tangco, P. Herranz, J. Rebollo, J. M. Vieitez |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
medicine.medical_specialty medicine.medical_treatment Breast Neoplasms Gastroenterology Carboplatin chemistry.chemical_compound Bolus (medicine) Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Neoplasm Metastasis Aged Mitoxantrone Chemotherapy business.industry Hematology Middle Aged medicine.disease Metastatic breast cancer Surgery Regimen Oncology chemistry Fluorouracil Toxicity Drug Evaluation Female business medicine.drug |
| Zdroj: | Annals of Oncology. 3:545-548 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/oxfordjournals.annonc.a058257 |
| Popis: | Fifty-five women with metastatic breast cancer were treated with carboplatin (CBDCA), 55 mg/m2 i.v. bolus, daily for 3 days, 5-fluorouracil (5-FU) 900 mg/m2, (max. dose 1,500 mg/day in 24-h infusion (Travenol system) daily for 3 days, and mitoxantrone (DHAD) 8 mg/m2, i.v. bolus on day 1. Cycles were administered every 5 weeks. Objective responses were observed in 25 (44%) patients (95% confidence interval: 28%-60%) with a median duration of remission of 11.5+ months (range 6.5(+)-31+). Toxicity was mild. These results reflect the fact that combination of CBDCA, 5-FU and DHAD is effective and very well tolerated as an outpatient regimen. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|